Catch up on what happened in optometry during the week of November 27-December 1.
Catch up with what Optometry Times®' shared this week:
Sydney M Crago, Editor, Modern Retina
The Vision Council has released the results of their Provider InSights research study for Q3 2023. This study explores the sentiments of eye care providers in relation to the daily operations of their practices, the eye care industry, and the American economy and was conducted in October and November of 2023. Those surveyed include opticians, optometrists, ophthalmologists, eye care practice managers, eye care practice owners and other professionals.
Mile Brujic, OD, FAAO; Lynda Charters
Managing patients with dry eye disease may not be as clear-cut as it appears. Mile Brujic, OD, FAAO, shared his pearls with 2 challenging cases at a recent Ophthalmology Times and Optometry Times Case-Based Roundtable. He is a partner in the Premier Vision Group in Bowling Green, Ohio.
David Hutton, Managing Editor, Ophthalmology Times
Aldeyra Therapeutics Inc announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.
Robert L. Rosenthal, OD
"This case [in this article] illustrates so many things about how to run a successful contact lens practice. First, I don’t ever want my patients to hear about new technology from someone else. I make it a priority that my staff and I stay abreast of the latest innovations so that we can offer better products before patients start complaining—and certainly before they are ready to drop out of lens wear."
Benjamin P. Casella, OD, FAAO
One meta-analysis of 145 studies estimates that myopia, which affected 22% of individuals globally in 2000, will be present in 50% of the world’s population by 2050.1 This seems like quite a staggering statistic until you hone in on the developed countries in East Asia, where the prevalence of myopia in school-aged children is 80% to 90%.